Develops technology mapping cell-cell communication within human tissue for translational research and drug development.
| Date | Round | Amount |
|---|---|---|
| May 2026 | Funding round Moleculent (Stockholm) raised $20M led by Rubicon Healthcare Partners, with ARCH Venture Partners and Eir Ventures, to scale its platform for analyzing cell interactions in tissue and expand into the US. | $20M |
| Jun 2024 | Series A Moleculent closed an oversubscribed $26M Series A co-led by ARCH Venture Partners and Eir Ventures to advance its cell-communication mapping platform. | $26M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.